These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 17877812

  • 1. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
    Hayase T.
    BMC Neurosci; 2007 Sep 18; 8():76. PubMed ID: 17877812
    [Abstract] [Full Text] [Related]

  • 2. Nicotine (NC)-induced "depressive" behavioral symptoms and effects of antidepressants including cannabinoids (CBs).
    Hayase T.
    J Toxicol Sci; 2008 Dec 18; 33(5):555-64. PubMed ID: 19043277
    [Abstract] [Full Text] [Related]

  • 3. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V.
    Int Rev Neurobiol; 2009 Dec 18; 85():57-72. PubMed ID: 19607961
    [Abstract] [Full Text] [Related]

  • 4. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
    Hayase T.
    BMC Neurosci; 2013 Feb 09; 14():20. PubMed ID: 23394117
    [Abstract] [Full Text] [Related]

  • 5. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
    Yamaguchi T, Tsujimatsu A, Kumamoto H, Izumi T, Ohmura Y, Yoshida T, Yoshioka M.
    J Ethnopharmacol; 2012 Sep 28; 143(2):533-9. PubMed ID: 22819689
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
    Patel S, Hillard CJ.
    J Pharmacol Exp Ther; 2006 Jul 28; 318(1):304-11. PubMed ID: 16569753
    [Abstract] [Full Text] [Related]

  • 7. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors.
    Urigüen L, Pérez-Rial S, Ledent C, Palomo T, Manzanares J.
    Neuropharmacology; 2004 Jun 28; 46(7):966-73. PubMed ID: 15081793
    [Abstract] [Full Text] [Related]

  • 8. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
    Consoli D, Leggio GM, Mazzola C, Micale V, Drago F.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):139-47. PubMed ID: 17669397
    [Abstract] [Full Text] [Related]

  • 9. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
    Bhutada P, Mundhada Y, Bansod K, Ubgade A, Quazi M, Umathe S, Mundhada D.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug 16; 34(6):955-60. PubMed ID: 20447436
    [Abstract] [Full Text] [Related]

  • 10. The benzodiazepine diazepam demonstrates the usefulness of Syrian hamsters as a model for anxiety testing: evaluation of other classes of anxiolytics in comparison to diazepam.
    Gannon RL, Lungwitz E, Batista N, Hester I, Huntley C, Peacock A, Delagrange P, Millan MJ.
    Behav Brain Res; 2011 Mar 17; 218(1):8-14. PubMed ID: 21094664
    [Abstract] [Full Text] [Related]

  • 11. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
    Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig-Lipson S, Day M.
    Neuropharmacology; 2008 Jun 17; 54(7):1136-42. PubMed ID: 18423777
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors.
    Hayase T.
    BMC Pharmacol; 2011 Jul 18; 11():6. PubMed ID: 21767384
    [Abstract] [Full Text] [Related]

  • 13. Prenatal cocaine and/or nicotine exposure produces depression and anxiety in aging rats.
    Sobrian SK, Marr L, Ressman K.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May 18; 27(3):501-18. PubMed ID: 12691787
    [Abstract] [Full Text] [Related]

  • 14. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
    Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E.
    Neuropharmacology; 2006 Sep 18; 51(3):578-86. PubMed ID: 16828124
    [Abstract] [Full Text] [Related]

  • 15. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors.
    Peng WH, Wu CR, Chen CS, Chen CF, Leu ZC, Hsieh MT.
    Life Sci; 2004 Oct 01; 75(20):2451-62. PubMed ID: 15350820
    [Abstract] [Full Text] [Related]

  • 16. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
    Chaki S, Hirota S, Funakoshi T, Suzuki Y, Suetake S, Okubo T, Ishii T, Nakazato A, Okuyama S.
    J Pharmacol Exp Ther; 2003 Feb 01; 304(2):818-26. PubMed ID: 12538838
    [Abstract] [Full Text] [Related]

  • 17. Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor.
    Hayase T.
    PLoS One; 2016 Feb 01; 11(7):e0158950. PubMed ID: 27404492
    [Abstract] [Full Text] [Related]

  • 18. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE.
    Neuropeptides; 2007 Oct 01; 41(5):307-20. PubMed ID: 17637475
    [Abstract] [Full Text] [Related]

  • 19. Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice.
    Biala G, Kruk M.
    J Pharm Pharmacol; 2009 Apr 01; 61(4):493-502. PubMed ID: 19298697
    [Abstract] [Full Text] [Related]

  • 20. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
    Bespalov AY, van Gaalen MM, Sukhotina IA, Wicke K, Mezler M, Schoemaker H, Gross G.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):96-102. PubMed ID: 18634781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.